1
|
Bidan N, Dunsmore G, Ugrinic M, Bied M, Moreira M, Deloménie C, Ginhoux F, Blériot C, de la Fuente M, Mura S. Multicellular tumor spheroid model to study the multifaceted role of tumor-associated macrophages in PDAC. Drug Deliv Transl Res 2024; 14:2085-2099. [PMID: 38062286 DOI: 10.1007/s13346-023-01479-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/07/2023] [Indexed: 06/27/2024]
Abstract
While considerable efforts have been made to develop new therapies, progress in the treatment of pancreatic cancer has so far fallen short of patients' expectations. This is due in part to the lack of predictive in vitro models capable of accounting for the heterogeneity of this tumor and its low immunogenicity. To address this point, we have established and characterized a 3D spheroid model of pancreatic cancer composed of tumor cells, cancer-associated fibroblasts, and blood-derived monocytes. The fate of the latter has been followed from their recruitment into the tumor spheroid to their polarization into a tumor-associated macrophage (TAM)-like population, providing evidence for the formation of an immunosuppressive microenvironment.This 3D model well reproduced the multiple roles of TAMs and their influence on drug sensitivity and cell migration. Furthermore, we observed that lipid-based nanosystems consisting of sphingomyelin and vitamin E could affect the phenotype of macrophages, causing a reduction of characteristic markers of TAMs. Overall, this optimized triple coculture model gives a valuable tool that could find useful application for a more comprehensive understanding of TAM plasticity as well as for more predictive drug screening. This could increase the relevance of preclinical studies and help identify effective treatments.
Collapse
Affiliation(s)
- Nadège Bidan
- Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400, Orsay, France
| | | | - Martina Ugrinic
- Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400, Orsay, France
| | - Mathilde Bied
- Inserm U1015, Gustave Roussy, 94800, Villejuif, France
| | - Marco Moreira
- Inserm U1015, Gustave Roussy, 94800, Villejuif, France
| | - Claudine Deloménie
- Inserm US31, CNRS UAR3679, Ingénierie Et Plateformes Au Service de L'Innovation Thérapeutique (UMS-IPSIT), Université Paris-Saclay, 91400, Orsay, France
| | | | - Camille Blériot
- Inserm U1015, Gustave Roussy, 94800, Villejuif, France
- CNRS UMR8253, Institut Necker Enfants Malades, 75015, Paris, France
| | - Maria de la Fuente
- Nano-Oncology and Translational Therapeutics Group, Health Research Institute of Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706, Santiago de Compostela, Spain
- Biomedical Research Networking Center On Oncology (CIBERONC), 28029, Madrid, Spain
- DIVERSA Technologies SL, 15782, Santiago de Compostela, Spain
| | - Simona Mura
- Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400, Orsay, France.
| |
Collapse
|
2
|
Tiryaki E, Ortolano S, Bodelón G, Salgueiriño V. Programming an Enhanced Uptake and the Intracellular Fate of Magnetic Microbeads. Adv Healthc Mater 2023; 12:e2301415. [PMID: 37660272 DOI: 10.1002/adhm.202301415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 08/28/2023] [Indexed: 09/04/2023]
Abstract
This study compares two kinds of magnetic microbeads with different surface features and cell entry pathways, aiming to provide insights into how to program their cell uptake and intracellular fate. It is found that a rougher surface enhances the cell uptake of the microbeads, regardless of whether they are pulled by a magnetic field gradient or adsorbed by the cell membrane. However, the entry route affects the intracellular localization of the microbeads: The magnetically dragged microbeads reach the cytoplasm, while the adsorbed microbeads stay in the late endosomes and lysosomes. This suggests that different strategies can be used to target different cellular compartments with magnetic microbeads. Moreover, it is demonstrated that the cells containing the microbeads can be moved and regrown at specific locations by applying a magnetic field gradient, showing the potential of these magnetic microbeads for cell delivery and manipulation.
Collapse
Affiliation(s)
- Ecem Tiryaki
- CINBIO, Universidade de Vigo, Vigo, 36310, Spain
| | - Saida Ortolano
- Rare Diseases and Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Álvaro Cunqueiro, Vigo, 36312, Spain
| | - Gustavo Bodelón
- CINBIO, Universidade de Vigo, Vigo, 36310, Spain
- Departamento de Biología Funcional y Ciencias de la Salud, Universidade de Vigo, Vigo, 36310, Spain
| | - Verónica Salgueiriño
- CINBIO, Universidade de Vigo, Vigo, 36310, Spain
- Departamento de Física Aplicada, Universidade de Vigo, Vigo, 36310, Spain
| |
Collapse
|
3
|
Lores S, Gámez-Chiachio M, Cascallar M, Ramos-Nebot C, Hurtado P, Alijas S, López López R, Piñeiro R, Moreno-Bueno G, de la Fuente M. Effectiveness of a novel gene nanotherapy based on putrescine for cancer treatment. Biomater Sci 2023. [PMID: 36790445 DOI: 10.1039/d2bm01456d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Gene therapy has long been proposed for cancer treatment. However, the use of therapeutic nucleic acids presents several limitations such as enzymatic degradation, rapid clearance, and poor cellular uptake and efficiency. In this work we propose the use of putrescine, a precursor for higher polyamine biosynthesis for the preparation of cationic nanosystems for cancer gene therapy. We have formulated and characterized putrescine-sphingomyelin nanosystems (PSN) and studied their endocytic pathway and intracellular trafficking in cancer cells. After loading a plasmid DNA (pDNA) encoding the apoptotic Fas Ligand (FasL), we proved their therapeutic activity by measuring the cell death rate after treatment of MDA-MB-231 cells. We have also used xenografted zebrafish embryos as a first in vivo approach to demonstrate the efficacy of the proposed PSN-pDNA formulation in a more complex model. Finally, intratumoral and intraperitoneal administration to mice-bearing MDA-MB-231 xenografts resulted in a significant decrease in tumour cell growth, highlighting the potential of the developed gene therapy nanoformulation for the treatment of triple negative breast cancer.
Collapse
Affiliation(s)
- Saínza Lores
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain. .,Universidade de Santiago de Compostela (USC), Praza do Obradoiro, s/n, Santiago de Compostela, 15782, A Coruña, Spain
| | - Manuel Gámez-Chiachio
- Translational Cancer Research Laboratory, Department of Biochemistry, Autonomous University of Madrid, School of Medicine, "Alberto Sols" Biomedical Research Institute CSIC-UAM, IdiPaz, Arturo Duperier 4, 28029, Madrid, Spain. .,Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain
| | - María Cascallar
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain. .,Universidade de Santiago de Compostela (USC), Praza do Obradoiro, s/n, Santiago de Compostela, 15782, A Coruña, Spain.,Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain
| | - Carmen Ramos-Nebot
- Translational Cancer Research Laboratory, Department of Biochemistry, Autonomous University of Madrid, School of Medicine, "Alberto Sols" Biomedical Research Institute CSIC-UAM, IdiPaz, Arturo Duperier 4, 28029, Madrid, Spain. .,Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain
| | - Pablo Hurtado
- Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain.,Roche-CHUS Join Unit. Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.
| | - Sandra Alijas
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain. .,Roche-CHUS Join Unit. Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.
| | - Rafael López López
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain. .,Universidade de Santiago de Compostela (USC), Praza do Obradoiro, s/n, Santiago de Compostela, 15782, A Coruña, Spain.,Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain.,Roche-CHUS Join Unit. Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.
| | - Roberto Piñeiro
- Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain.,Roche-CHUS Join Unit. Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain.
| | - Gema Moreno-Bueno
- Translational Cancer Research Laboratory, Department of Biochemistry, Autonomous University of Madrid, School of Medicine, "Alberto Sols" Biomedical Research Institute CSIC-UAM, IdiPaz, Arturo Duperier 4, 28029, Madrid, Spain. .,Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain.,MD Anderson International Foundation, Gómez Hemans s/n, 28033 Madrid, Spain
| | - María de la Fuente
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spain. .,Universidade de Santiago de Compostela (USC), Praza do Obradoiro, s/n, Santiago de Compostela, 15782, A Coruña, Spain.,Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain.,DIVERSA Technologies SL, Edificio Emprendia, Universidade de Santiago de Compostela, Campus Vida s/n, 15782 Santiago de Compostela, Spain
| |
Collapse
|
4
|
Xie W, Gan Y, Zhang Y, Wang P, Zhang J, Qian J, Zhang G, Wu Z. Transition-metal-doped hydrophilic ultrasmall iron oxide modulates MRI contrast performance for accurate diagnosis of orthotopic prostate cancer. J Mater Chem B 2022; 10:9613-9621. [PMID: 36331033 DOI: 10.1039/d2tb01860h] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The FDA-approved iron oxide nanocrystals (IONs), as negative magnetic resonance imaging contrast agents (MRICAs), face challenges because of their low relaxation rate and coherent ferromagnetism. Although research has found that metal doping is an efficient approach to improve the magnetic property and MRI contrast performance of IONs, their systemic mechanism has not been fully explained. Herein, we fabricated a series of transition-metal-doped IONs and systemically explored their sizes, structures, and variation in magnetic properties, revealing the oxygen vacancy-mediated MRI contrast enhancement mechanism of transition-metal-doped IONs. Based on these, we found that Zn-doped IONs possess optimal T2 MRI contrast performance and further investigated their potential to diagnose in vivo orthotopic tumor as a T2 contrast agent. The results indicate that the use of Zn-doped IONs significantly enhances T2-weighted MRI signal intensity of orthotopic prostate tumor with low toxicity, which is beneficial for the accurate diagnosis of orthotopic tumor. Collectively, this work clearly illustrates the mechanism of contrast enhancement of transition-metal-doped IONs and provides a novel paradigm for developing a highly efficient T2 contrast agent.
Collapse
Affiliation(s)
- Wenteng Xie
- Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, P. R. China. .,University of Science and Technology of China, Hefei 230026, P. R. China
| | - Yuehao Gan
- Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, P. R. China. .,University of Science and Technology of China, Hefei 230026, P. R. China
| | - Ya'nan Zhang
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai 264003, P. R. China. .,Institute of Biomedical Imaging Probe, Binzhou Medical University, Yantai 264003, P. R. China
| | - Peng Wang
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai 264003, P. R. China. .,Institute of Biomedical Imaging Probe, Binzhou Medical University, Yantai 264003, P. R. China
| | - Jia Zhang
- Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, P. R. China.
| | - Junchao Qian
- Hefei Cancer Hospital, Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, P. R. China.
| | - Guilong Zhang
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai 264003, P. R. China. .,Institute of Biomedical Imaging Probe, Binzhou Medical University, Yantai 264003, P. R. China
| | - Zhengyan Wu
- Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, P. R. China.
| |
Collapse
|
5
|
Precision Nanotoxicology in Drug Development: Current Trends and Challenges in Safety and Toxicity Implications of Customized Multifunctional Nanocarriers for Drug-Delivery Applications. Pharmaceutics 2022; 14:pharmaceutics14112463. [PMID: 36432653 PMCID: PMC9697541 DOI: 10.3390/pharmaceutics14112463] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 11/06/2022] [Accepted: 11/13/2022] [Indexed: 11/17/2022] Open
Abstract
The dire need for the assessment of human and environmental endangerments of nanoparticulate material has motivated the formulation of novel scientific tools and techniques to detect, quantify, and characterize these nanomaterials. Several of these paradigms possess enormous possibilities for applications in many of the realms of nanotoxicology. Furthermore, in a large number of cases, the limited capabilities to assess the environmental and human toxicological outcomes of customized and tailored multifunctional nanoparticles used for drug delivery have hindered their full exploitation in preclinical and clinical settings. With the ever-compounded availability of nanoparticulate materials in commercialized settings, an ever-arising popular debate has been egressing on whether the social, human, and environmental costs associated with the risks of nanomaterials outweigh their profits. Here we briefly review the various health, pharmaceutical, and regulatory aspects of nanotoxicology of engineered multifunctional nanoparticles in vitro and in vivo. Several aspects and issues encountered during the safety and toxicity assessments of these drug-delivery nanocarriers have also been summarized. Furthermore, recent trends implicated in the nanotoxicological evaluations of nanoparticulate matter in vitro and in vivo have also been discussed. Due to the absence of robust and rigid regulatory guidelines, researchers currently frequently encounter a larger number of challenges in the toxicology assessment of nanocarriers, which have also been briefly discussed here. Nanotoxicology has an appreciable and significant part in the clinical translational development as well as commercialization potential of nanocarriers; hence these aspects have also been touched upon. Finally, a brief overview has been provided regarding some of the nanocarrier-based medicines that are currently undergoing clinical trials, and some of those which have recently been commercialized and are available for patients. It is expected that this review will instigate an appreciable interest in the research community working in the arena of pharmaceutical drug development and nanoformulation-based drug delivery.
Collapse
|
6
|
Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer. Pharm Pat Anal 2022; 11:155-162. [PMID: 36200656 DOI: 10.4155/ppa-2021-0029] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aim: To overcome the limitations associated with conventional formulations for cancer treatment by the effective utilization of nanoemulsion with therapy and diagnosis through the single unit. Patent: US20210275687 describes the usage of functionalized various oil-in-water nanoemulsions as pharmacological vehicles with theranostic potential in cancer treatment. Materials & methods: Vitamin E, oleic acid, sphingomyelin, ligands for functionalization, contrast agents and therapeutic biomolecules. Results: The toxicity studies conducted on healthy mice did not show any apparent toxicity issues. The stability studies conducted at 40 °C and 75% relative humidity, which is mandatory for regulatory approval, indicated the adequate physical stability of the formulation. Conclusion: The studies exhibited the promising theranostic potential of the developed nanoemulsion for the effective management and diagnosis of cancer and metastatic diseases.
Collapse
|
7
|
Chan MH, Huang WT, Chen KC, Su TY, Chan YC, Hsiao M, Liu RS. The optical research progress of nanophosphors composed of transition elements in the fourth period of near-infrared windows I and II for deep-tissue theranostics. NANOSCALE 2022; 14:7123-7136. [PMID: 35353112 DOI: 10.1039/d2nr00343k] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Research in the field of nano-optics is advancing by leaps and bounds, among which near-infrared (NIR) light optics have attracted much attention. NIR light has a longer wavelength than visible light, such that it can avoid shielding caused by biological tissues. This advantage has driven its importance and practicality in human treatment applications and has attracted significant attention from researchers in academia and industry. In the broad spectrum of infrared light wavelengths, the most noticeable ones are the NIR biological window I of 700-900 nm and window II of 1000-1700 nm. Luminescent materials can effectively cover the NIR biological window with different doping strategies. These doped elements are mostly transition elements with multielectron orbitals. Several nanomaterials based on narrow-spectrum lanthanides have been developed to correspond to biological applications of different wavelengths. However, this review explicitly introduces the absorption and reflection/luminescence interactions between NIR light and biological tissues independently. Unlike the adjustment of the wavelength of the lanthanide series, this review analyzes the NIR optical properties of the fourth-period element ions in transition elements (such as Cr3+ and Ni2+). These elements have a broadband wavelength of NIR light emission and higher quantum efficiency, corresponding to the absorption and emission spectrum and photobiological absorption of different NIR windows for therapeutic diagnosis. Finally, this review lists and explores other broadband NIR phosphors and has tried to discover the possibility of non-invasive precision medicine in the future.
Collapse
Affiliation(s)
- Ming-Hsien Chan
- Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
| | - Wen-Tse Huang
- Department of Chemistry, National Taiwan University, Taipei, 10617, Taiwan.
| | - Kuan-Chun Chen
- Department of Chemistry, National Taiwan University, Taipei, 10617, Taiwan.
| | - Ting-Yi Su
- Department of Chemistry, National Taiwan University, Taipei, 10617, Taiwan.
| | - Yung-Chieh Chan
- Intelligent Minimally Invasive Device Center, National Chung Hsing University, Taichung 40227, Taiwan
| | - Michael Hsiao
- Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
- Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
| | - Ru-Shi Liu
- Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
- Department of Chemistry, National Taiwan University, Taipei, 10617, Taiwan.
| |
Collapse
|
8
|
Nanoparticles of Bioactive Metals/Metal Oxides and Their Nanocomposites with Antibacterial Drugs for Biomedical Applications. MATERIALS 2022; 15:ma15103602. [PMID: 35629629 PMCID: PMC9147160 DOI: 10.3390/ma15103602] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 05/15/2022] [Accepted: 05/16/2022] [Indexed: 02/04/2023]
Abstract
The increasing appearance of new strains of microorganisms resistant to the action of existing antibiotics is a modern problem that requires urgent decision. A promising potential solution is the use of nanoparticles of bioactive metals and their oxides as new antibacterial agents, since they are capable of affecting pathogenic microorganisms by mechanisms different from the mechanisms of action of antibiotics. Inorganic nanoparticles possess a wide spectrum of antibacterial activity. These particles can be easily conjugated with drug molecules and become carriers in targeted drug-delivery systems. This paper discusses the benefits and prospects of the application of nanoparticles from metals and metal oxides and their nanocomposites with antibacterial drugs.
Collapse
|
9
|
Dependence of Structural, Morphological and Magnetic Properties of Manganese Ferrite on Ni-Mn Substitution. Int J Mol Sci 2022; 23:ijms23063097. [PMID: 35328516 PMCID: PMC8949668 DOI: 10.3390/ijms23063097] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Revised: 03/01/2022] [Accepted: 03/11/2022] [Indexed: 02/01/2023] Open
Abstract
This paper presents the influence of Mn2+ substitution by Ni2+ on the structural, morphological and magnetic properties of Mn1−xNixFe2O4@SiO2 (x = 0, 0.25, 0.50, 0.75, 1.00) nanocomposites (NCs) obtained by a modified sol-gel method. The Fourier transform infrared spectra confirm the formation of a SiO2 matrix and ferrite, while the X-ray diffraction patterns show the presence of poorly crystalline ferrite at low annealing temperatures and highly crystalline mixed cubic spinel ferrite accompanied by secondary phases at high annealing temperatures. The lattice parameters gradually decrease, while the crystallite size, volume, and X-ray density of Mn1−xNixFe2O4@SiO2 NCs increase with increasing Ni content and follow Vegard’s law. The saturation magnetization, remanent magnetization, squareness, magnetic moment per formula unit, and anisotropy constant increase, while the coercivity decreases with increasing Ni content. These parameters are larger for the samples with the same chemical formula, annealed at higher temperatures. The NCs with high Ni content show superparamagnetic-like behavior, while the NCs with high Mn content display paramagnetic behavior.
Collapse
|
10
|
Bidan N, Lores S, Vanhecke A, Nicolas V, Domenichini S, López R, de la Fuente M, Mura S. Before in vivo studies: In vitro screening of sphingomyelin nanosystems using a relevant 3D multicellular pancreatic tumor spheroid model. Int J Pharm 2022; 617:121577. [PMID: 35167901 DOI: 10.1016/j.ijpharm.2022.121577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 02/07/2022] [Accepted: 02/09/2022] [Indexed: 12/13/2022]
Abstract
Sphingomyelin nanosystems have already shown to be promising carriers for efficient delivery of anticancer drugs. For further application in the treatment of pancreatic tumor, the investigation on relevant in vitro models able to reproduce its physio-pathological complexity, is mandatory. Accordingly, a 3D heterotype spheroid model of pancreatic tumor has been herein constructed to investigate the potential of bare and polyethylene glycol-modified lipids nanosystems in terms of their ability to penetrate the tumor mass and deliver drugs. Regardless of their surface properties, the lipid nanosystems successfully diffused through the spheroid without inducing toxicity, showing a clear safety profile. Loading of the bare nanosystems with a lipid prodrug of gemcitabine was used to evaluate their therapeutic potential. While the nanosystems were more effective than the free drug on 2D cell monocultures, this advantage, despite their efficient penetration capacity, was lost in the 3D tumor model. The latter, being able to mimic the tumor and its microenvironment, was capable to provide a more realistic information on the cell sensitivity to treatments. These results highlight the importance of using appropriate 3D tumour models as tools for proper in vitro evaluation of nanomedicine efficacy and their timely optimisation, so as to identify the best candidates for later in vivo evaluation.
Collapse
Affiliation(s)
- Nadege Bidan
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F92296 Châtenay-Malabry cedex, France
| | - Saínza Lores
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain
| | - Aure Vanhecke
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F92296 Châtenay-Malabry cedex, France
| | - Valérie Nicolas
- UMS-IPSIT MIPSIT Microscopy facility, Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 92296, Châtenay-Malabry, France
| | - Severine Domenichini
- UMS-IPSIT MIPSIT Microscopy facility, Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 92296, Châtenay-Malabry, France
| | - Rafael López
- Translational Medical Oncology group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; Biomedical Research Networking Center on Oncology (CIBERONC), Madrid, 28029, Spain
| | - María de la Fuente
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; Biomedical Research Networking Center on Oncology (CIBERONC), Madrid, 28029, Spain.
| | - Simona Mura
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F92296 Châtenay-Malabry cedex, France.
| |
Collapse
|
11
|
Jatal R, Mendes Saraiva S, Vázquez-Vázquez C, Lelievre E, Coqueret O, López-López R, de la Fuente M. Sphingomyelin nanosystems decorated with TSP-1 derived peptide targeting senescent cells. Int J Pharm 2022; 617:121618. [DOI: 10.1016/j.ijpharm.2022.121618] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2021] [Revised: 02/08/2022] [Accepted: 02/21/2022] [Indexed: 12/23/2022]
|
12
|
Masoumi F, Saraiva SM, Bouzo BL, López-López R, Esteller M, Díaz-Lagares Á, de la Fuente M. Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem. Pharmaceutics 2021; 13:pharmaceutics13091507. [PMID: 34575588 PMCID: PMC8470159 DOI: 10.3390/pharmaceutics13091507] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 09/06/2021] [Accepted: 09/14/2021] [Indexed: 01/01/2023] Open
Abstract
Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer.
Collapse
Affiliation(s)
- Farimah Masoumi
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; (F.M.); (S.M.S.); (B.L.B.)
- Immunology Department, School of Medicine, Tehran University of Medical Sciences, Tehran 14176-13151, Iran
- School of Medicine, Tonekabon Branch, Islamic Azad University, Tonekabon 46841-61167, Iran
| | - Sofia M. Saraiva
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; (F.M.); (S.M.S.); (B.L.B.)
- Centro de Investigación Biomédica en Red de Cancer (CIBERONC), 28029 Madrid, Spain; (R.L.-L.); (M.E.)
| | - Belén L. Bouzo
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; (F.M.); (S.M.S.); (B.L.B.)
| | - Rafael López-López
- Centro de Investigación Biomédica en Red de Cancer (CIBERONC), 28029 Madrid, Spain; (R.L.-L.); (M.E.)
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain
| | - Manel Esteller
- Centro de Investigación Biomédica en Red de Cancer (CIBERONC), 28029 Madrid, Spain; (R.L.-L.); (M.E.)
- Josep Carreras Leukaemia Research Institute (IJC), 08916 Barcelona, Spain
- Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), 08907 Barcelona, Spain
- Institucio Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Ángel Díaz-Lagares
- Centro de Investigación Biomédica en Red de Cancer (CIBERONC), 28029 Madrid, Spain; (R.L.-L.); (M.E.)
- Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS), SERGAS, 15706 Santiago de Compostela, Spain
- Correspondence: (A.D.-L.); (M.d.l.F.)
| | - María de la Fuente
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; (F.M.); (S.M.S.); (B.L.B.)
- Centro de Investigación Biomédica en Red de Cancer (CIBERONC), 28029 Madrid, Spain; (R.L.-L.); (M.E.)
- Correspondence: (A.D.-L.); (M.d.l.F.)
| |
Collapse
|